IDT Biologika Overview
- Year Founded
-
1921
- Status
-
Acquired/Merged
- Employees
-
1,800
- Latest Deal Type
-
M&A
- Financing Rounds
-
4
- Investments
-
4
IDT Biologika General Information
Description
Manufacturer of biotechnology-based vaccines and pharmaceuticals designed to improve the health of humans and animals. The company's vaccines and pharmaceuticals are sterile, injectable and bioengineered and are made out of prophylactic and therapeutic biologics making them capable of fighting against infectious diseases enabling international biopharmaceutical companies to combat diseases and epidemics worldwide.
Contact Information
Website
www.idt-biologika.com(Operating Subsidiary)
Corporate Office
- Am Pharmapark
- 06861 Dessau-Rosslau
- Germany
Corporate Office
- Am Pharmapark
- 06861 Dessau-Rosslau
- Germany
IDT Biologika Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IDT Biologika Comparisons
Industry
Financing
Details
IDT Biologika Competitors (29)
One of IDT Biologika’s 29 competitors is TCG Lifesciences, a Corporation company based in Kolkata, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TCG Lifesciences | Corporation | Kolkata, India | ||||
| Vector Biolabs | Corporation | PA | ||||
| CordenPharma | Private Equity-Backed | Basel, Switzerland | ||||
| Charles River Laboratories International | Formerly PE-Backed | Wilmington, MA | ||||
| OncoResponse | Venture Capital-Backed | Houston, TX |
IDT Biologika Patents
IDT Biologika Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020115329-A1 | A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv | Inactive | 07-Dec-2018 | ||
| EP-2949340-A1 | Vaccine composition against streptococcus suis infection | Inactive | 30-May-2014 | ||
| US-20170209561-A1 | Vaccine composition against streptococcus suis infection | Inactive | 30-May-2014 | ||
| WO-2015181356-A1 | Vaccine composition against streptococcus suis infection | Inactive | 30-May-2014 | ||
| WO-2015181356-A8 | Vaccine composition against streptococcus suis infection | Inactive | 30-May-2014 | A61K39/092 |
IDT Biologika Signals
IDT Biologika Acquisitions (4)
IDT Biologika’s most recent deal was a Merger/Acquisition with Ridgeway Biologicals. The deal was made on 05-Jan-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ridgeway Biologicals | 05-Jan-2017 | Merger/Acquisition | Drug Discovery | ||
| Gallant Custom Laboratories | 31-Aug-2015 | Merger/Acquisition | Other Consumer Non-Durables | ||
| Aeras Global TB Vaccine Foundation (Biopharmaceutical Development Center) | 23-Jun-2015 | Merger/Acquisition | Drug Discovery | ||
| RIEMSER Arzneimittel (Animal Health Business) | 01-Aug-2013 | Merger/Acquisition | Drug Delivery |
IDT Biologika Exits (1)
IDT Biologika’s most recent exit was on 05-Jan-2017 from Ridgeway Biologicals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Ridgeway Biologicals | 05-Jan-2017 | Completed |
|
IDT Biologika Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Gallant Custom Laboratories | Cambridge, Canada | 1995 |
IDT Biologika FAQs
-
When was IDT Biologika founded?
IDT Biologika was founded in 1921.
-
Where is IDT Biologika headquartered?
IDT Biologika is headquartered in Dessau-Rosslau, Germany.
-
What is the size of IDT Biologika?
IDT Biologika has 1,800 total employees.
-
What industry is IDT Biologika in?
IDT Biologika’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is IDT Biologika a private or public company?
IDT Biologika is a Private company.
-
What is the current valuation of IDT Biologika?
The current valuation of IDT Biologika is .
-
What is IDT Biologika’s current revenue?
The current revenue for IDT Biologika is .
-
How much funding has IDT Biologika raised over time?
IDT Biologika has raised $324M.
-
Who are IDT Biologika’s competitors?
TCG Lifesciences, Vector Biolabs, CordenPharma, Charles River Laboratories International, and OncoResponse are some of the 29 competitors of IDT Biologika.
-
When was IDT Biologika acquired?
IDT Biologika was acquired on 01-Oct-2024.
-
Who acquired IDT Biologika?
IDT Biologika was acquired by SK Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process